Cargando…
Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain
Purpose: We aimed to explore the characteristics, and real-life therapeutic management of patients with breakthrough cancer pain (BTcP) caused by bone metastases in Spain, and to evaluate physicians’ opinion of and satisfaction with prescribed BTcP therapy. Participants and methods: For the purposes...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636433/ https://www.ncbi.nlm.nih.gov/pubmed/31372030 http://dx.doi.org/10.2147/JPR.S194881 |
_version_ | 1783436060845408256 |
---|---|
author | Ferrer Albiach, Carlos Villegas Estévez, Francisco López Alarcón, Mª Dolores de Madariaga, María Carregal, Alfonso Arranz, Javier Trinidad Martín-Arroyo, José M Jiménez López, Antonio Javier Sanz Yagüe, Almudena |
author_facet | Ferrer Albiach, Carlos Villegas Estévez, Francisco López Alarcón, Mª Dolores de Madariaga, María Carregal, Alfonso Arranz, Javier Trinidad Martín-Arroyo, José M Jiménez López, Antonio Javier Sanz Yagüe, Almudena |
author_sort | Ferrer Albiach, Carlos |
collection | PubMed |
description | Purpose: We aimed to explore the characteristics, and real-life therapeutic management of patients with breakthrough cancer pain (BTcP) caused by bone metastases in Spain, and to evaluate physicians’ opinion of and satisfaction with prescribed BTcP therapy. Participants and methods: For the purposes of this study, an ad-hoc questionnaire was developed consisting of two domains: a) organizational aspects and care standards; b) clinical and treatment variables of bone metastatic BTcP patients. In addition, physicians’ satisfaction with their prescribed BTcP therapy was assessed. Specialists collected data from up to five patients receiving treatment for BTcP caused by bone metastasis, all patients gave their consent to participate prior to inclusion. Results: A total of 103 cancer pain specialists (radiation oncologists [38.8%], pain specialists [33.0%], and palliative care (PC) specialists [21.4%]) were polled, and data on 386 BTcP patients with bone metastatic disease were collected. Only 33% of the specialists had implemented specific protocols for BTcP management, and 19.4% had established referral protocols for this group of patients. Half of all participants (50.5%) address quality of life and quality of care in their patients; however, only 27.0% did so from the patient’s perspective, as they should do. Most patients had multiple metastases and were prescribed rapid-onset fentanyl preparations (71.2%), followed by immediate-release morphine (9.3%) for the treatment of BTcP. Rapid-onset fentanyl was prescribed more often in PC units (79.0%) than in pain units (75.9%) and radiation oncology units (61.1%) (p<0.01). Furthermore, most physicians (71.8%) were satisfied with the BTcP therapy prescribed. Conclusions: Our results demonstrate the need for routine assessment of quality of life in patients with bone BTcP. These findings also underscore the necessity for a multidisciplinary therapeutic strategy for breakthrough pain in clinical practice in Spain. |
format | Online Article Text |
id | pubmed-6636433 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-66364332019-08-01 Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain Ferrer Albiach, Carlos Villegas Estévez, Francisco López Alarcón, Mª Dolores de Madariaga, María Carregal, Alfonso Arranz, Javier Trinidad Martín-Arroyo, José M Jiménez López, Antonio Javier Sanz Yagüe, Almudena J Pain Res Original Research Purpose: We aimed to explore the characteristics, and real-life therapeutic management of patients with breakthrough cancer pain (BTcP) caused by bone metastases in Spain, and to evaluate physicians’ opinion of and satisfaction with prescribed BTcP therapy. Participants and methods: For the purposes of this study, an ad-hoc questionnaire was developed consisting of two domains: a) organizational aspects and care standards; b) clinical and treatment variables of bone metastatic BTcP patients. In addition, physicians’ satisfaction with their prescribed BTcP therapy was assessed. Specialists collected data from up to five patients receiving treatment for BTcP caused by bone metastasis, all patients gave their consent to participate prior to inclusion. Results: A total of 103 cancer pain specialists (radiation oncologists [38.8%], pain specialists [33.0%], and palliative care (PC) specialists [21.4%]) were polled, and data on 386 BTcP patients with bone metastatic disease were collected. Only 33% of the specialists had implemented specific protocols for BTcP management, and 19.4% had established referral protocols for this group of patients. Half of all participants (50.5%) address quality of life and quality of care in their patients; however, only 27.0% did so from the patient’s perspective, as they should do. Most patients had multiple metastases and were prescribed rapid-onset fentanyl preparations (71.2%), followed by immediate-release morphine (9.3%) for the treatment of BTcP. Rapid-onset fentanyl was prescribed more often in PC units (79.0%) than in pain units (75.9%) and radiation oncology units (61.1%) (p<0.01). Furthermore, most physicians (71.8%) were satisfied with the BTcP therapy prescribed. Conclusions: Our results demonstrate the need for routine assessment of quality of life in patients with bone BTcP. These findings also underscore the necessity for a multidisciplinary therapeutic strategy for breakthrough pain in clinical practice in Spain. Dove 2019-07-12 /pmc/articles/PMC6636433/ /pubmed/31372030 http://dx.doi.org/10.2147/JPR.S194881 Text en © 2019 Ferrer Albiach et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Ferrer Albiach, Carlos Villegas Estévez, Francisco López Alarcón, Mª Dolores de Madariaga, María Carregal, Alfonso Arranz, Javier Trinidad Martín-Arroyo, José M Jiménez López, Antonio Javier Sanz Yagüe, Almudena Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain |
title | Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain |
title_full | Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain |
title_fullStr | Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain |
title_full_unstemmed | Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain |
title_short | Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain |
title_sort | real-life management of patients with breakthrough cancer pain caused by bone metastases in spain |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636433/ https://www.ncbi.nlm.nih.gov/pubmed/31372030 http://dx.doi.org/10.2147/JPR.S194881 |
work_keys_str_mv | AT ferreralbiachcarlos reallifemanagementofpatientswithbreakthroughcancerpaincausedbybonemetastasesinspain AT villegasestevezfrancisco reallifemanagementofpatientswithbreakthroughcancerpaincausedbybonemetastasesinspain AT lopezalarconmadolores reallifemanagementofpatientswithbreakthroughcancerpaincausedbybonemetastasesinspain AT demadariagamaria reallifemanagementofpatientswithbreakthroughcancerpaincausedbybonemetastasesinspain AT carregalalfonso reallifemanagementofpatientswithbreakthroughcancerpaincausedbybonemetastasesinspain AT arranzjavier reallifemanagementofpatientswithbreakthroughcancerpaincausedbybonemetastasesinspain AT trinidadmartinarroyojosem reallifemanagementofpatientswithbreakthroughcancerpaincausedbybonemetastasesinspain AT jimenezlopezantoniojavier reallifemanagementofpatientswithbreakthroughcancerpaincausedbybonemetastasesinspain AT sanzyaguealmudena reallifemanagementofpatientswithbreakthroughcancerpaincausedbybonemetastasesinspain |